爱美医疗(FOLD)高管介绍_美股行情_同花顺金融网

Ted W. Love，自2009年3月Love博士曾担任Bio-Rad公司（Bio-Rad\'s Board）董事会和审计委员会成员，从2010年2月至2012年8月担任Onyx制药公司（Onyx Pharmaceuticals, Inc.），一家公开上市的生物制药公司的研发和技术运营领导及执行副总裁，从2001年到2009年1月Love博士担任Nuvelo公司（Nuvelo, Inc.），一家公开上市的生物制药公司的董事长兼首席执行官。加入Nuvelo之前，从1998年到2001年Love博士在Theravance公司（Theravance, Inc.），一家生物制药公司担任开发部高级副总裁，他在Genentech公司（Genentech, Inc.）任职六年时间，担任过多个医疗事务和产品开发高级管理职位，并担任Genentech公司（Genentech, Inc.）的产品开发委员会主席。Love博士还担任生物制药企业Santarus公司（biopharmaceutical companies Santarus, Inc.），Amicus公司（Amicus, Inc.），ADVENTRX公司（Adventrx, Inc.），Affymax公司（Affymax, Inc.）和BioRad公司（ BioRad, Inc.）的董事会成员，直到2012年4月，他担任加州独立公民监督委员会（the California Independent Citizens\' Oversight Committee）委员。Love博士获得了哈弗福德学院（Haverford College）分子生物学理学学士学位以及耶鲁大学医学院（Yale Medical School）医学博士学位。

Ted W. Love, M.D., has served as a member of the Board since June 2012. Dr. Love is currently the CEO of Global Blood Therapeutics, Inc. NASDAQ: GBT. From February 2010 to August 2012 Dr. Love served as Executive Vice President and Head of Research and Development of Onyx Pharmaceuticals, Inc. From 2001 to 2009 Dr. Love was the President, Chief Executive Officer and Chairman of the Board of Directors of Nuvelo Inc. Before joining Nuvelo in 2001 he served as Senior Vice President of Development at Theravance, Inc. Prior to that, Dr. Love spent six years at Genentech, Inc. in a number of senior management positions in Medical Affairs and Product Development. As Vice President of Product Development and Regulatory Affairs at Genentech, Dr. Love oversaw all drugs in development including Herceptin, Rituxan, and TNKase. He also served as chairman of Genentech\'s Product Development Committee. In addition to Amicus, Dr. Love currently serves on the Board of Directors of Global Blood and was previously a board member of Cascadian Therapeutics. Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School. Ted W. Love，自2009年3月Love博士曾担任Bio-Rad公司（Bio-Rad\'s Board）董事会和审计委员会成员，从2010年2月至2012年8月担任Onyx制药公司（Onyx Pharmaceuticals, Inc.），一家公开上市的生物制药公司的研发和技术运营领导及执行副总裁，从2001年到2009年1月Love博士担任Nuvelo公司（Nuvelo, Inc.），一家公开上市的生物制药公司的董事长兼首席执行官。加入Nuvelo之前，从1998年到2001年Love博士在Theravance公司（Theravance, Inc.），一家生物制药公司担任开发部高级副总裁，他在Genentech公司（Genentech, Inc.）任职六年时间，担任过多个医疗事务和产品开发高级管理职位，并担任Genentech公司（Genentech, Inc.）的产品开发委员会主席。Love博士还担任生物制药企业Santarus公司（biopharmaceutical companies Santarus, Inc.），Amicus公司（Amicus, Inc.），ADVENTRX公司（Adventrx, Inc.），Affymax公司（Affymax, Inc.）和BioRad公司（ BioRad, Inc.）的董事会成员，直到2012年4月，他担任加州独立公民监督委员会（the California Independent Citizens\' Oversight Committee）委员。Love博士获得了哈弗福德学院（Haverford College）分子生物学理学学士学位以及耶鲁大学医学院（Yale Medical School）医学博士学位。 Ted W. Love, M.D., has served as a member of the Board since June 2012. Dr. Love is currently the CEO of Global Blood Therapeutics, Inc. NASDAQ: GBT. From February 2010 to August 2012 Dr. Love served as Executive Vice President and Head of Research and Development of Onyx Pharmaceuticals, Inc. From 2001 to 2009 Dr. Love was the President, Chief Executive Officer and Chairman of the Board of Directors of Nuvelo Inc. Before joining Nuvelo in 2001 he served as Senior Vice President of Development at Theravance, Inc. Prior to that, Dr. Love spent six years at Genentech, Inc. in a number of senior management positions in Medical Affairs and Product Development. As Vice President of Product Development and Regulatory Affairs at Genentech, Dr. Love oversaw all drugs in development including Herceptin, Rituxan, and TNKase. He also served as chairman of Genentech\'s Product Development Committee. In addition to Amicus, Dr. Love currently serves on the Board of Directors of Global Blood and was previously a board member of Cascadian Therapeutics. Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School.